☆ 4.3 Article

Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data

JOURNAL OF SEXUAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Review Urology & Nephrology

Retrospective Observational Real-World Outcome Study to Evaluate Safety Among Patients With Erectile Dysfunction (ED) With Co-Possession of Tadalafil and Anti-Hypertensive Medications (anti-HTN)

Anthony P. Nunes et al.

Summary: This study aimed to evaluate the risk of hypotensive/cardiovascular outcomes associated with co-possession of tadalafil and anti-hypertensive medications, and the results showed that this co-possession does not increase the risk of adverse outcomes.

JOURNAL OF SEXUAL MEDICINE (2022)

Add to Collection

Article Economics

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force

Don Husereau et al.

Summary: The CHEERS 2022 statement replaces the previous reporting guidance and provides recommendations for accurate reporting and interpretation of health economic evaluations. It addresses different types of evaluations, new methods and developments, and includes stakeholder involvement. It is important for researchers, peer reviewers, editors, analysts, and health technology assessment bodies seeking guidance on reporting.

VALUE IN HEALTH (2022)

Add to Collection

Review Medicine, General & Internal

Gliflozins in the Management of Cardiovascular Disease

Eugene Braunwald

Summary: Gliflozins, a type of medication used to treat type 2 diabetes, not only lowers blood glucose levels but also improves cardiac and renal function.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Cell Biology

Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial

Riccardo Pofi et al.

Summary: This study found that PDE5 inhibitors can improve cardiac remodeling in male patients with diabetic cardiomyopathy, but not in female patients. Additionally, the use of this inhibitor also improves cardiovascular, metabolic, immune, and renal function in both sexes. However, further research is still needed to confirm whether Klotho and hsa-miR-199-5p are markers for T2DM complications.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk

Rishi Rikhi et al.

Summary: Multiple lines of evidence confirm that reducing low-density lipoprotein-cholesterol is crucial in reducing the risk of atherosclerotic cardiovascular disease. However, adherence to statin therapy is low and many patients fail to reach target low-density lipoprotein-cholesterol levels. Therefore, new and emerging approaches are discussed in this review to find more aggressive strategies for lowering low-density lipoprotein-cholesterol.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Rheumatology

Erectile Dysfunction and Cardiovascular Risk in Men With Rheumatoid Arthritis: A Cohort

Katelynn M. Wilton et al.

Summary: The study revealed that the incidence of erectile dysfunction (ED) is not statistically increased in patients with rheumatoid arthritis (RA). Although men with both RA and ED have a similar cardiovascular risk to those with RA alone, they have a decreased risk of heart failure, myocardial infarction, and death.

JOURNAL OF RHEUMATOLOGY (2021)

Add to Collection

Review Urology & Nephrology

Reno-protective effects of Phosphodiesterase 5 inhibitors

Enis Rauf Coskuner et al.

Summary: The kidneys are important organs responsible for various functions, and kidney diseases can be caused by multiple factors, with inflammation and oxidative stress playing crucial roles. Acute and chronic kidney diseases are associated with long hospital stays, increased morbidity, and mortality.

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2021)

Add to Collection

Article Urology & Nephrology

Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States

Anthony P. Nunes et al.

Summary: This real-world study found that co-possession of nitrate and PDE5i prescriptions is not associated with an increased risk of cardiovascular outcomes. Most cardiovascular outcome rates were not significantly different between co-possession and ED + PDE5i periods, although some outcomes were higher with co-possession. Many patients discussed the risks of co-possession with their physicians and received warnings or instructions.

JOURNAL OF SEXUAL MEDICINE (2021)

Add to Collection

Review Medicine, General & Internal

Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses

Nikolaos Pyrgidis et al.

Summary: Phosphodiesterase-type 5 inhibitors are recommended first-line treatment for erectile dysfunction, being safe and effective in various patient groups. This overview aims to summarize the existing knowledge on the efficacy and safety of PDE5i in the general population and multiple patient subgroups.

BMJ OPEN (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease

Daniel P. Andersson et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

Karen A. Hicks et al.

CIRCULATION (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Validating Publicly Available Crosswalks for Translating ICD-9 to ICD-10 Diagnosis Codes for Cardiovascular Outcomes Research

Jesse A. Columbo et al.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction

Daniel P. Andersson et al.

HEART (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: A nationwide cohort study

Nanna Vestergaard et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)

Add to Collection

Article Endocrinology & Metabolism

Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes

Geoffrey Hackett et al.

WORLD JOURNAL OF DIABETES (2017)

Add to Collection

Review Endocrinology & Metabolism

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

C. Corinaldesi et al.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality

Simon G. Anderson et al.

HEART (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Therapeutic Potentials of Phosphodiesterase-5 Inhibitors in Cardiovascular Disease

Ha Nguyen et al.

REVIEWS IN CARDIOVASCULAR MEDICINE (2014)

Add to Collection

Review Medicine, General & Internal

Phosphodiesterase Type 5 Inhibitors Improve Endothelial Function and May Benefit Cardiovascular Conditions

Bryan G. Schwartz et al.

AMERICAN JOURNAL OF MEDICINE (2013)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cardiac Uses of Phosphodiesterase-5 Inhibitors

Bryan G. Schwartz et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)

Add to Collection

Article Public, Environmental & Occupational Health

Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries

Hude Quan et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2011)

Add to Collection

Article Pharmacology & Pharmacy

Anti-platelet therapy: phosphodiesterase inhibitors

Paolo Gresele et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)

Add to Collection

Review Pharmacology & Pharmacy

Mechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile Dysfunction

K. -E. Andersson

PHARMACOLOGICAL REVIEWS (2011)

Add to Collection

Review Statistics & Probability

Matching Methods for Causal Inference: A Review and a Look Forward

Elizabeth A. Stuart

STATISTICAL SCIENCE (2010)

Add to Collection

Article Cardiac & Cardiovascular Systems

Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease

Carmine Gazzaruso et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)

Add to Collection

Article Urology & Nephrology

The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size

C. Sesti et al.

INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2007)

Add to Collection

Article Urology & Nephrology

Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk

GMC Rosanoa et al.

EUROPEAN UROLOGY (2005)

Add to Collection

Article Health Care Sciences & Services

Validity of procedure codes in International Classification of Diseases, 9th revision, clinical modification administrative data

H Quan et al.

MEDICAL CARE (2004)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation

T Reffelmann et al.

CARDIOVASCULAR RESEARCH (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.